You are here: Industry Insights > Eisai

News List

Eisai, BMS Enter Global Anticancer ADC Alliance contractpharma
June 21, 2021
Eisai Co., Ltd. and Bristol-Myers Squibb Co. entered an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC).
Eisai Begins Construction of New Injection/Research Building contractpharma
March 23, 2021
Eisai Co., Ltd., as part of a strategic investment, began construction of a new injection/research building "Eisai Medicine Innovation Technology Solutions" (EMITS) at the Kawashima Industrial Park in Gifu Prefecture, Japan.
Eisai’s anti-cancer agent LENVIMA receives orphan drug designation pharmaceutical-technology
March 16, 2021
Japanese pharmaceutical company Eisai has received orphan drug designation for its anti-cancer agent LENVIMA with a prospective indication for uterine body cancer.
Wren Therapeutics raises £12.4m in latest financing round pharmatimes
January 27, 2021
Cambridge, UK-based biopharmaceutical company Wren Therapeutics has completed the closing of £12.4m financing, taking its total capital raised to date to around £33m.
Eisai Appoints Chief Clinical Officer of Oncology Biz contractpharma
January 21, 2021
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., has appointed Dr. Richard Woodman as Chief Clinical Officer of its Oncology Business Group.
Biogen applies for approval of Alzheimer’s drug, aducanumab in Japan expresspharma
December 11, 2020
Biogen said it has filed for regulatory approval in Japan for an Alzheimer’s disease drug it developed with local partner Eisai.
Eisai and Wren Therapeutics to collaborate for drug discovery for synucleinopathies expresspharma
December 01, 2020
This collaboration aims to develop a disease modifying treatment for synucleinopathies based on network kinetics of α-synuclein misfolding and aggregation.
Eisai Invests in New Packaging Lines contractpharma
November 17, 2020
Eisai has made an £11.5 million ($15.2 million) investment to fund two new packaging lines and create new jobs at its Hatfield production plant in Hertfordshire.
Lenvima plus Keytruda achieves primary endpoints in trial for RCC europeanpharmaceuticalreview
November 12, 2020
Lenvima and Keytruda has demonstrated positive top-line results in a Phase III trial in patients with advanced renal cell carcinoma.
EMA accepts marketing application for Biogen, Eisai’s Alzheimer’s therapy pharmaceutical-technology
November 04, 2020
Biogen and Eisai have announced that the European Medicines Agency (EMA) accepted to review the marketing authorisation application (MAA) for aducanumab, an investigational antibody therapy for Alzheimer’s disease.

Previous page 1 2 3 4 5 6 7 8 9 10 Next page